Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer

Background: Immunotherapy (IT) has led to improved survival in several common cancers but success in pancreatic ductal adenocarcinoma (PDAC) has been limited. We analyzed if combination IT–chemotherapy (IT-CT) is associated with improved survival compared with chemotherapy alone (CT) in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hue, Jonathan J., Bingmer, Katherine, Sugumar, Kavin, Markt, Sarah C., Rothermel, Luke D., Hardacre, Jeffrey M., Ammori, John B., Winter, Jordan M., Ocuin, Lee M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080907/
https://www.ncbi.nlm.nih.gov/pubmed/33937617
http://dx.doi.org/10.1089/pancan.2021.0003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080907/
https://www.ncbi.nlm.nih.gov/pubmed/33937617
http://dx.doi.org/10.1089/pancan.2021.0003

Ejemplares similares